Cefiderocol
A novel siderophore cephalosporin antibiotic that uses the iron transport system of bacteria to actively penetrate bacterial cells, overcoming many resistance mechanisms. It is indicated for the treatment of carbapenem-resistant gram-negative bacteria, including Acinetobacter, which are extremely difficult to treat. Its unique iron-chelating mechanism allows it to remain effective even against many multidrug-resistant organisms.
Peso molecular
752,2000 g/mol
LogP
1,00
TPSA
310,00 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)CS[C@H]12)c1csc(N)n1)C(=O)O
InChI
InChI=1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/t20-,26-/m1/s1
Molecular Formula
C30H34ClN7O10S2
HBD / HBA
6 / 15
Enlaces Rotables
12
Átomos Pesados
50
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A novel siderophore cephalosporin antibiotic that uses the iron transport system of bacteria to actively penetrate bacterial cells, overcoming many resistance mechanisms. It is indicated for the treatment of carbapenem-resistant gram-negative bacteria, including Acinetobacter, which are extremely difficult to treat. Its unique iron-chelating mechanism allows it to remain effective even against many multidrug-resistant organisms.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefiderocol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989974. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 77843966. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefiderocol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefiderocol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefiderocol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefiderocol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefiderocol"></drugfyi-drug>